Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

News Releases

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions
October 10, 2018
Ron Dadino appointed Vice President, Pharmaceutical Development & Operations, Cardiovascular Interventions Greg Kopia, Ph.D., CMPP appointed Director, Pre-Clinical Development, Cardiovascular Interventions Ziv Belsky appointed Vice President, Research & Development, Cardiac Neuromodulation New
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
October 9, 2018
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first successful pediatric heart transplant Jason Aryeh, life sciences industry expert, investment fund manager, and Director of
Orchestra BioMed™ Bolsters Leadership Team with Appointment of Inessa Wheeler as Vice President, Strategy and Marketing
October 8, 2018
Ms. Wheeler brings an extensive track record in marketing, strategy and commercial program development New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical
Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018
September 25, 2018
Immediate, Substantial, and Sustained Reduction in Blood Pressure Demonstrates Potential to Offer Highly Differentiated, Breakthrough Treatment for Hypertension San Diego, CA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational
Orchestra BioMed™ Announces Presentation of 3-Year Clinical Results for Virtue® Sirolimus-Eluting Balloon at TCT 2018
September 24, 2018
Excellent Long-Term Safety and Efficacy Profile Demonstrate Potential to Offer Valuable New Treatment for Coronary In-Stent Restenosis San Diego, CA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices
Three-Month Data from the Moderato-HTN Trial Published
December 23, 2017
American Heart Association Journal 3-months data from Moderato-HTN first-in-human clinical study was published in the American Heart Association Journal. The study was an open-label, single-arm, multicenter, prospective trial investigating the safety and efficacy of BackBeat PHC pacing therapy in
Abstract on BackBeat® CNT Awarded Best Abstract at the International Conference for Innovations
December 5, 2017
International Conference for Innovation (ICI), Tel Aviv, Israel BackBeat’s abstract entitled “Two-Year Experience with Programmable Hypertension Control Therapy: A Novel Treatment for Hypertension” was awarded best abstract at the International Conference for Innovation (ICI) that took place in Tel
Angiographic Results and 1-Year Clinical Outcomes from the SABRE Trial Published
October 23, 2017
JACC: Cardiovascular Interventions Angiographic results and 1-year clinical outcomes of the SABRE (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) trial were published in JACC: Cardiovascular Interventions, October 2017. ABSTRACT. Objectives The aim of this first-in-human study was
BackBeat Medical Wins Top Honor in TCT 2016 Shark Tank Innovation Competition
November 4, 2016
Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC. New Hope, PA – BackBeat Medical Inc. today announced that the company's patented Programmable Hypertension Control (PHC) therapy received first place in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular
Results of Multicenter Clinical Study Demonstrate BackBeat's Patented Technology Creates a Potential Breakthrough in Device-Based Treatment of Hypertension
August 28, 2016
The Journal of Innovation in Cardiac Rhythm Management BackBeat Medical Inc. today announced the presentation of data demonstrating a significant and sustained reduction in blood pressure in patients with hypertension using the company's patented cardiac pacing-based treatment.

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
Displaying 31 - 40 of 40
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer